对于性结肠炎治疗的pH依赖药物输送系统
Yana Gvozdeva1,2, Radiana Staynova3
1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Pharmaceutics
|February 26, 2025
概括
依赖pH的药物输送系统为炎症性肠道疾病 (IBD) 提供了一个有希望的解决方案,比如性结肠炎 (UC). 这些系统针对结肠,提高治疗效率,减少副作用.
科学领域:
- 胃肠病学 胃肠病学
- 药品制造 药品制造 药品制造
- 生物材料科学 生物材料科学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病,对全球健康构成重大挑战.
- 目前的IBD治疗方法往往不足,无法满足患者的需求,原因是药物的有效性和输送受到限制.
- 性结肠炎 (UC) 涉及结肠粘膜的广泛炎症,需要针对性的治疗干预.
研究的目的:
- 审查pH依赖药物输送系统在UC中针对结肠治疗的优点和局限性.
- 探索pH敏感载体如何克服向炎症结肠输送药物的挑战.
- 突出针对性药物输送在改善UC治疗结果方面的潜力.
主要方法:
- 对使用pH敏感聚合物进行向释放的pH依赖药载体的讨论.
- 分析传统药物输送系统在达到结肠时所面临的挑战.
- 审查胃肠道 (GIT) 中的不同pH值如何被利用来控制药物释放.
主要成果:
- 依赖pH的载体显示出局部药物作用在结肠中的潜力,减少全身副作用.
- 这些系统保护药物免受降解,并在上部GIT中过早清除.
- 向性输送可以提高炎症结肠组织的药物可用性,从而改善治疗结果.
结论:
- 依赖pH的药物输送系统代表了UC治疗的重大进步.
- 通过pH响应系统向结肠提供有针对性的输送,可以提高疗效和耐受性.
- 对这些系统的进一步研究可以优化炎症性肠道疾病的治疗策略.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
01:29Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89
01:26Peptic Ulcer Disease IV: Management
58
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
58
01:17Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140